SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Takeda logo
3 weeks ago

Sr. Manager, Commercial Content Business / Product Owner 

Takeda

Lexington, MA (On-site)Full time$137K/yr – $215K/yr
Takeda logo
4 weeks ago

Associate Director, IBD Consumer Marketing

Takeda

Cambridge, MA (On-site)Full time$154K/yr – $243K/yr
Takeda logo
5 weeks ago

Digital Marketing Manager

Takeda

Boston, MA (Hybrid)Full time$162K/yr – $182K/yr
Takeda logo
5 weeks ago

Manager, Commercial Content Business/Product Owner  

Takeda

Lexington, MA (Hybrid)Full time$116K/yr – $182K/yr
Takeda logo
2 months ago

Associate Director, Field Marketing - South East

Takeda

Florida, NY (Remote)Full time$154K/yr – $243K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Takeda logo

Sr. Manager, Commercial Content Business / Product Owner 

Takeda

Lexington, MA (On-site)

$137K/yr - $215K/yrIn-houseFull-timeSenior level5+ years exp.
3 weeks ago
Takeda logo

Associate Director, IBD Consumer Marketing

Takeda

Cambridge, MA (On-site)

$154K/yr - $243K/yrIn-houseFull-timeSenior level7+ years exp.
4 weeks ago
Takeda logo

Digital Marketing Manager

Takeda

Boston, MA (Hybrid)

$162K/yr - $182K/yrIn-houseFull-timeSenior level4+ years exp.
5 weeks ago
Takeda logo

Manager, Commercial Content Business/Product Owner  

Takeda

Lexington, MA (Hybrid)

$116K/yr - $182K/yrIn-houseFull-timeManager5+ years exp.
5 weeks ago
Takeda logo

Associate Director, Field Marketing - South East

Takeda

Florida, NY (Remote)

$154K/yr - $243K/yrIn-houseFull-timeMid level3+ years exp.
2 months ago
Takeda logo
Takeda

Sr. Manager, Commercial Content Business / Product Owner 

Lexington, MA (On-site)

$137K/yr – $215K/yrSenior Level5+ years expFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the data and governance spine for content operations, turning DAM and workflow tooling into a compliant, scalable platform across brands and channels.

  • Platform governance: set the Martech roadmap and cross-brand adoption for DAM and related tools.
  • Metadata and tagging: establish taxonomy and workflows to boost discoverability and performance tracking.
  • Modular content reuse: enable reuse across brands with standardized DAM/workflow setup and hands-off processes.

Job Description

Responsibilities

  • Platform strategy and governance: Define the Marketing Technology roadmap and governance for content operations platforms, including DAM and related workflow/fulfillment tools with DD&T
  • Tagging and metadata standards: Define taxonomy/metadata requirements and tagging workflows so content is consistently tagged, discoverable, and performance-trackable
  • Enable modular content reuse: Configure DAM/workflow platforms and standards to support modular content development, assembly, and reuse across brands and channels
  • Partner with TA content leads and Ad/Promo: Translate TA needs and review feedback into platform enhancements and process improvements; ensure clear roles, handoffs, and consistent use of tooling across brands
  • Drive adoption and support model: Define the operating model for user support, training, communications, and issue escalation; ensure consistent adoption across internal teams, agencies, and partners
  • Vendor and platform relationship management: Manage key platform and service partners, including SLAs, prioritizations, escalations, and continuous improvement; coordinate platform training updates with partners
  • Manage license and budget levers: Oversee platform licensing and key vendor relationships; manage enhancement funding and prioritize spend against highest value capabilities
  • Enable compliant content operations: Ensure the MarTech ecosystem supports compliant development and approval of promotional materials in a regulated environment, embedding required controls and documentation practices

Requirements

  • Bachelor’s degre e required , Preferred Advanced degree (MBA, MS, PharmD, or related).
  • 5–8+ years managing marketing technology platforms (e.g., DAM, workflow, content ops), defining roadmaps, adoption frameworks, and governance standards across brands or business units.
  • Proven experience partnering with brand, Ad/Promo, TA content leads, and agencies to translate business needs into platform enhancements, process improvements, and compliant content operations.
  • Experience managing platform vendors and service partners, negotiating SLAs, prioritizing enhancements, and overseeing licensing budgets or funding allocations.
  • Strong understanding of regulated content development requirements, metadata/tagging standards, modular content reuse, and operational controls to enable scalable, compliant, and measurable content workflows.

Benefits

  • short-term and/ or long-term incentives
  • medical, dental, vision insurance
  • a 401(k) plan and company match
  • short-term and long-term disability coverage
  • b asic life insurance
  • a tuition reimbursement program
  • paid volunteer time off
  • company holidays
  • well-being benefits
  • up to 80 hours of sick time per calendar year
Takeda logo

Takeda

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society.We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities.Read our community guidelines: https://takeda.info/communityguidelines

Tokyo, Tokyo, JPN
37K employees (1,941 in marketing)
www.takeda.com

Traffic Signals

Monthly Visitors
586.5K
Monthly Google Ads Budget
$3.3K
Traffic Source Mix
Search
49%
Direct
38.4%
Referral
8.4%
Social
2.1%
Paid
1.9%

Headcount Trend

Current headcount: ~37.2K

Marketing Team

Marketing Team Size
1,695 (5% of company)
Median Career Experience
16 years
Median Tenure
5.3 years
Marketing Roles Posted (Last 30 Days)
15

People

HR / Recruitment

Cristal Mikenas
Cristal Mikenas
Head of Employer Brand & Recruitment Marketing
At the company for 5 years 2 months
Emma James
Emma James
Global Recruitment Marketing Manager
At the company for 4 years 5 months

Marketing Leadership

Heather Schaefer
Heather Schaefer
Vice President, Patient Access Brand Strategy & Operations
At the company for 10 years 10 months
Kylie J. Wagner
Kylie J. Wagner
Head, Marketing and BU Customer Engagement
At the company for 21 years 3 months
Anne de Schweinitz
Anne de Schweinitz
Head, Global Corporate Brand and Content
At the company for 1 year 11 months
Matthew O'Rourke
Matthew O'Rourke
Sr. Director - Head of BioLife Brand and Insights
At the company for 2 years 1 month

Funding

Total Funding
$2.5B
Last Raise
$2.4B
Post IPO Debt, 9 months ago

Funding History

  • Jun 2025
    Post IPO Debt • $2.4B
  • Sep 2016
    Grant • $19.8M
  • May 2016
    Grant • $38M

Recent News

ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap
Dec 8, 2025 • Fierce Biotech
Takeda Pharmaceutical (TSE:4502): Exploring Valuation After Recent Shareholder Gains
Nov 22, 2025 • Yahoo Finance
FDA launches investigation into Takeda's Adzynma following reported pediatric death
Nov 21, 2025 • Fierce Pharma
US FDA investigates Takeda's blood disorder drug after pediatric death
Nov 21, 2025 • Reuters
FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy
Nov 21, 2025 • BioSpace
Setting a sustainable course for the pharma industry | Takeda Stories
Nov 13, 2025 • Takeda Pharmaceuticals
Neurocrine's depression drug is latest asset from Takeda pact to flunk a phase 2 trial
Nov 11, 2025 • Fierce Biotech
Former FDA comms director James-Denton Wyllie joins Takeda Pharmaceuticals
Nov 10, 2025 • PRWeek
Takeda Pharmaceutical (TSE:4502): Assessing Valuation After Subtle Share Price Changes
Nov 8, 2025 • Yahoo Finance
Takeda’s Phase III TIDES Trial Confirms Long-Term Efficacy and Safety of Qdenga Dengue Vaccine
Nov 4, 2025 • Applied Clinical Trials Online
Takeda’s dengue vaccine offers seven-year protection in pivotal trial
Nov 3, 2025 • Clinical Trials Arena
Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss
Nov 1, 2025 • Yahoo Finance
Fierce Pharma Asia—Takeda pipeline cuts; Innovent, Lilly win against semaglutide; Roche's bispecific deal
Oct 31, 2025 • Fierce Pharma
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
Oct 30, 2025 • Yahoo Finance
Takeda drops AstraZeneca-partnered neurological program after phase 2 failure
Oct 30, 2025 • Fierce Biotech
Takeda discloses pivotal Innovent plans | ApexOnco - Clinical Trials news and analysis
Oct 30, 2025 • Oncology Pipeline
Takeda's shares fall as it trims full-year guidance, pipeline
Oct 30, 2025 • FirstWord Pharma
In a Potential Mega Deal, Takeda Buys Innovent Cancer Candidates
Oct 29, 2025 • Inside Precision Medicine
Takeda, TetraScience set SAIL on AI-powered drug discovery
Oct 24, 2025 • FirstWord Pharma
Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls
Oct 23, 2025 • Pharmaceutical Technology
Takeda Boosts Pipeline and Revenue Growth Prospects With $1.2B Deal for Innovent Cancer Drugs
Oct 22, 2025 • MedCity News
China’s Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion - WSJ
Oct 22, 2025 • The Wall Street Journal
Takeda pays Innovent $1.2B upfront, offers whopping $10B-plus in biobucks for cancer assets
Oct 22, 2025 • Fierce Biotech
Takeda Licenses Late-Stage Cancer Drugs from Innovent in $1.2 Billion Deal
Oct 22, 2025 • Contract Pharma
Takeda stakes more than $11B on cancer drugs from China
Oct 22, 2025 • BioPharma Dive
China's Innovent signs cancer therapy deal with Japan's Takeda
Oct 22, 2025 • Yahoo Finance
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
Oct 22, 2025 • BioSpace
Takeda pays $1.2B upfront to transform oncology pipeline with two Innovent drugs
Oct 21, 2025 • FirstWord Pharma
Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio
Oct 21, 2025 • Yahoo Finance
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors
Oct 21, 2025 • Business Wire
Does Takeda Offer Value After Latest FDA Approval and Share Price Dip in 2025?
Oct 19, 2025 • Yahoo Finance
Nabla Bio expands Takeda collab for protein therapeutics
Oct 15, 2025 • Pharmaceutical Technology
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics
Oct 14, 2025 • Business Wire
US biotech Nabla Bio, Japan's Takeda expand AI drug design partnership
Oct 14, 2025 • Reuters
Takeda Makes $1B+ AI Bet With Nabla to Build Out Early Pipeline
Oct 14, 2025 • BioSpace
Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus
Oct 14, 2025 • Fierce Biotech
AI-based protein discovery start-up strikes a second deal with Takeda
Oct 14, 2025 • C&EN
Takeda Opens $170 Million Expansion
Oct 13, 2025 • Los Angeles Business Journal
Takeda Pharmaceutical (TSE:4502): Is the Market Missing Its True Valuation Potential?
Oct 9, 2025 • Yahoo Finance
How Takeda Built Its Cell Therapy Portfolio, Only To Walk Away
Oct 8, 2025 • BioSpace
Biopharmaceutical company Takeda to lay off more than 130 employees in Cambridge
Oct 7, 2025 • Wicked Local
Takeda calls for more Plasma Donations During International Plasma Awareness Week
Oct 7, 2025 • Takeda Pharmaceuticals
Takeda brings clinical data to life for AI
Oct 7, 2025 • Informatica
Aiming to stop Crohn's disease before it starts | Takeda Stories
Oct 6, 2025 • Takeda Pharmaceuticals
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery
Oct 3, 2025 • Yahoo Finance
気候変動に柔軟に対応する:2025年度CSRプログラム | 武田薬品
Oct 3, 2025 • Takeda Pharmaceuticals
Takeda Announces Decision to Discontinue Cell Therapy Research
Oct 2, 2025 • PharmExec.com
Takeda Exits Cell Therapy Amid Strategic Pivot, Dealing Blow to Once Promising Modality
Oct 2, 2025 • BioSpace
Takeda walks away from cell therapy in priority U-turn
Oct 2, 2025 • Clinical Trials Arena
Takeda’s cancer prospects dim further | ApexOnco - Clinical Trials news and analysis
Oct 2, 2025 • Oncology Pipeline
Takeda to cut 137 staffers after cell therapy exit
Oct 2, 2025 • FirstWord Pharma
武田薬品、「細胞療法」の研究開発を中止 減損580億円計上見込み
Oct 1, 2025 • 日本経済新聞
Takeda unveils $170M expansion in Thousand Oaks
Oct 1, 2025 • Ventura County Star
UPDATED: Takeda lays off 137 US staff as part of retreat from cell therapy
Oct 1, 2025 • Fierce Biotech
Takeda, in reversal, abandons cell therapy research
Oct 1, 2025 • BioPharma Dive
Takeda Pharmaceutical to exit cell therapy research
Oct 1, 2025 • Reuters
Takeda Pharmaceutical to exit cell therapy research
Oct 1, 2025 • Yahoo Finance
Curtain closes on Takeda's cell therapy efforts
Oct 1, 2025 • FirstWord Pharma
武田薬品、血液製剤工場建設1年以上遅れ 建設費高騰で計画見直し
Sep 30, 2025 • 日本経済新聞
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
Sep 29, 2025 • BioSpace
6 FDA Decisions to Watch For in Q4
Sep 29, 2025 • BioSpace
Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
Sep 26, 2025 • IndiaTimes
Trump’s drug tariffs are days away. Massachusetts’ pharma companies aren’t worried.
Sep 26, 2025 • Boston Globe
Shares of Asian drugmakers drop after Trump threatens tariffs
Sep 26, 2025 • MarketScreener
Plasma donation powers rare disease treatments | Takeda Stories
Sep 25, 2025 • Takeda Pharmaceuticals
Shares of Asian drugmakers drop after Trump threatens tariffs
Sep 25, 2025 • Investing.com
6 Companies Hiring Now in Pennsylvania
Sep 25, 2025 • BioSpace
武田薬品、「貨物帆船」で医薬品を輸送、仏企業と提携 - ニュース - メガソーラービジネス plus
Sep 24, 2025 • 日経BP
【工場探訪:くすりづくりの現場を歩く】武田薬品工業・光工場―生産量の約半分を海外に輸出、デジタルによる業務改善・効率化随所に
Sep 24, 2025 • 転職×天職
20,000 + Takeda Employees Voted to Select Four New Global...
Sep 24, 2025 • PharmiWeb
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions
Sep 23, 2025 • PR Newswire UK
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries
Sep 23, 2025 • thecanadianpressnews.ca
Japan biotech inks research pact in effort to develop new RNA meds
Sep 19, 2025 • FierceBiotech
Wind-Powered Trimaran Cargo Ship To Be Launched In 2026
Sep 19, 2025 • Clean Technica
Takeda scientists tackle Mount Fuji to advocate for patients in need of plasma-derived therapies
Sep 19, 2025 • FiercePharma
Takeda eyes sustainable shipping with wind-powered sea freight
Sep 18, 2025 • European Pharmaceutical Review
Takeda Uses AI To Forecast Drug Demand, Cut Waste
Sep 17, 2025 • MarketScreener
From atop Mt. Fuji, a Takeda team heralds a need for human plasma
Sep 16, 2025 • PharmaVoice
Regulatory actions for Sept. 16, 2025
Sep 16, 2025 • BioWorld Financial Watch
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025 • FiercePharma
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
Sep 16, 2025 • AETOSWire
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran
Sep 16, 2025 • PharmiWeb
Takeda, Vela Transport announce medicine shipping partnership
Sep 16, 2025 • thefly.com
[新連載]武田薬品、急ピッチで進む「米国化」の実相 ボストンに全集中
Sep 12, 2025 • 日経ビジネス電子版
Takeda taps longtime Lilly exec as US head—Chutes & Ladders
Sep 12, 2025 • Fierce Biotech
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
Sep 12, 2025 • BioSpace
Former URI basketball star to lead Takeda's US operations
Sep 12, 2025 • Seattle TechFlash
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
Sep 11, 2025 • Business Wire
Former URI basketball star jumps from Eli Lilly to Takeda
Sep 11, 2025 • Seattle TechFlash
Takeda Announces Executive Changes, Effective September 29
Sep 11, 2025 • MarketScreener
United States Digestive Health Market Set to Soar: Key Trends, Innovations, and Growth Opportunities in 2025-2032
Sep 11, 2025 • EIN Presswire
Takeda recruits Lilly executive to run US operations out of Cambridge
Sep 11, 2025 • Boston Globe
Results of Nanoform Collaborative Study to be Presented a...
Sep 11, 2025 • PharmiWeb
Takeda Announces Executive Changes, Effective June 2026
Sep 11, 2025 • MarketScreener
Takeda faces another 'pay-for-delay' antitrust lawsuit, this one from CVS over heartburn drug Dexilant
Sep 10, 2025 • Fierce Pharma
AGC Biologics Seattle Facility Achieves Milestone Year wi...
Sep 10, 2025 • PharmiWeb
Takeda presents positive data from Phase III oveporexton study
Sep 10, 2025 • Pharma Letter
Assessing Takeda Stock After Recent 6% Jump and New FDA Approval for HyQvia Expansion
Sep 9, 2025 • Yahoo Finance
Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels
Sep 8, 2025 • MedCity News
Takeda and Alkermes share OX2R drug data for narcolepsy
Sep 8, 2025 • Clinical Trials Arena